Enovis (NYSE:ENOV) Sets New 52-Week Low – Here’s What Happened

Enovis Corporation (NYSE:ENOV) hit a new 52-week low during trading on Friday . The stock traded as low as $20.55 and last traded at $21.2060, with a volume of 1502415 shares traded. The stock had previously closed at $21.97.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on ENOV shares. Weiss Ratings restated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. William Blair started coverage on shares of Enovis in a research report on Friday, April 17th. They set an “outperform” rating on the stock. Wells Fargo & Company decreased their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Zacks Research lowered shares of Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $44.50.

Enovis Stock Down 3.5%

The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The firm’s 50-day moving average is $24.07 and its 200 day moving average is $24.63. The firm has a market capitalization of $1.22 billion, a PE ratio of -1.07 and a beta of 1.38.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million for the quarter, compared to analyst estimates of $572.02 million. During the same period in the previous year, the firm earned $0.81 EPS. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts forecast that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Enovis

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Enovis by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 6,524,235 shares of the company’s stock valued at $197,945,000 after purchasing an additional 125,460 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Enovis by 1.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,971,545 shares of the company’s stock valued at $90,156,000 after purchasing an additional 51,201 shares during the last quarter. Rubric Capital Management LP acquired a new position in Enovis in the 3rd quarter valued at about $83,435,000. Paradigm Capital Management Inc. NY raised its stake in Enovis by 70.2% in the 1st quarter. Paradigm Capital Management Inc. NY now owns 1,776,715 shares of the company’s stock valued at $40,420,000 after purchasing an additional 732,917 shares during the last quarter. Finally, River Road Asset Management LLC raised its stake in Enovis by 3.2% in the 4th quarter. River Road Asset Management LLC now owns 1,487,277 shares of the company’s stock valued at $39,621,000 after purchasing an additional 46,289 shares during the last quarter. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.